Glaxosmithkline Pharmaceuticals Q1 Results Revenue Drops to ₹81,100 Lakhs, and Profit After Tax Falls to ₹18,165 Lakhs

GlaxoSmithKline Pharmaceuticals Q1 Results: GlaxoSmithKline Pharmaceuticals released their Q1 financial results for the period ending June 30, 2024, on August 30, 2024. The company's revenue from operations reached ₹81,100 lakhs, marking a 10.4% decrease from the previous quarter’s revenue of ₹91,087 lakhs.

Despite this drop, the company's overall income for the quarter stood at ₹84,685 lakhs, compared to ₹94,074 lakhs in the preceding quarter, reflecting a decrease of 9.9% quarter-over-quarter. The company reported a profit before tax of ₹24,849 lakhs for Q1 2024, which is a slight decrease of 7.4% from the ₹26,871 lakhs reported in the previous quarter.

The profit after tax was ₹18,165 lakhs, down 6.2% from ₹19,308 lakhs in Q4 2023. This reduction in earnings is attributed to higher costs in materials and increased employee benefits expenses.

Despite these challenges, the company’s earnings per share remained stable, showing a slight decrease in basic and diluted EPS from ₹11.39 to ₹10.72, reflecting the impact of lower profits.

For More Q1 results check our Twitter Page

Glaxosmithkline Pharmaceuticals Q1 Results 2024 - 2025

Here is a summary of GlaxoSmithKline Pharmaceuticals's Q1 results for the period ending June 30, 2024. The company experienced a decrease in revenue and profit compared to the previous quarter. Below is the detailed financial data presented in a table:

Source: Here

Glaxosmithkline Pharmaceuticals Current Market Overview

GlaxoSmithKline Pharmaceuticals is currently trading at ₹2,745 per share, down by 0.78%. The company's market value is ₹46,504 crore. The stock has fluctuated between a high of ₹3,088 and a low of ₹1,385. With a Price-to-Earnings (P/E) ratio of 60.4, it is relatively high compared to its earnings.

The company has a book value of ₹105 per share and offers a dividend yield of 1.17%. It has strong financial metrics, with a Return on Capital Employed (ROCE) of 51.3% and a Return on Equity (ROE) of 37.3%. The stock's face value is ₹10.

Quarterly Results

Here is a summary of GlaxoSmithKline Pharmaceuticals's quarterly financial results for December 2023, March 2024, and June 2024:

The table below highlights the company's performance in these three recent quarters, focusing on sales, expenses, operating profit, and other key financial metrics.

About Glaxosmithkline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals, commonly known as GSK, is a major Indian pharmaceutical and healthcare company. Founded on November 13, 1924, it originally started as an agency house for distributing baby food and later became known as Laboratories (I) Ltd.

Today, GSK is a subsidiary of the global GSK group and specializes in producing prescription medicines and vaccines. Their products cover a wide range of health areas including anti-infectives, dermatology, diabetes, oncology, cardiovascular diseases, and respiratory conditions.

The company also offers vaccines for various diseases such as hepatitis, influenza, chickenpox, and more, aiming to improve public health through innovative solutions.

Visit our website for more Q1 results.